Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities | |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | ||
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein | |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen | |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies | |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler | |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities | |
| 10/2/2024 | $400.00 → $250.00 | Outperform → Market Perform | Leerink Partners |
4/A - Neuronetics, Inc. (0001227636) (Issuer)
4/A - Neuronetics, Inc. (0001227636) (Issuer)
4/A - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
Bernstein upgraded Humana from Mkt Perform to Outperform and set a new price target of $308.00
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo
Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 25, 2025 to stockholders of record as of the close of business on March 28, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military se
Reports 4Q24 net loss per share of $5.76 on a GAAP basis, Adjusted net loss per share of $2.16; reports FY 2024 earnings per share (EPS) of $9.98 on a GAAP basis, $16.21 on an Adjusted basis 4Q24 Insurance segment Adjusted benefit ratio of 91.9 percent, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations Affirms previous commentary of Adjusted FY 2025 EPS guidance to be 'at least in line with 2024 results'; anticipating GAAP EPS of approximately $15.88, or approximately $16.25 on an Adjusted basis, inclusive of incremental investments to support operational excellence Expects individual Medicare Advantage annua
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
SC 13D - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
DEFA14A - HUMANA INC (0000049071) (Filer)
DEF 14A - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
Humana Inc. (the "company") (NYSE:HUM) announced today the completion of its public offering of $1.25 billion in aggregate principal amount of senior notes. These senior notes are comprised of $750 million of the company's 5.550 percent senior notes, due 2035, at 99.885 percent of the principal amount, and $500 million of the company's 6.000 percent senior notes, due 2055, at 98.951 percent of the principal amount (collectively, the "Senior Notes Offerings"). The company expects net proceeds from the Senior Notes Offerings will be approximately $1.231 billion after deducting underwriters' discounts and estimated offering expenses. The company intends to use the net proceeds from the Senior
AM Best has assigned a Long-Term Issue Credit Rating of "bbb" (Good) to the $750 million, 5.5% senior unsecured notes, due 2035, and the $500 million, 6.0% senior unsecured notes, due 2055, issued by Humana Inc. (Humana) (headquartered in Louisville, KY) (NYSE:HUM). The outlook assigned to these Credit Ratings (ratings) is stable. Humana's Long-Term Issuer Credit Rating of "bbb" (Good), its Long-Term IRs and the ratings of its insurance subsidiaries are unchanged. Humana expects to use the proceeds from the senior unsecured notes issuance for general corporate purposes, including the repayment of existing debt of $600 million, 4.5% senior unsecured notes maturing in April 2025, and short-t
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on December 9, 2024Received an incremental $10 million in funding from Perceptive AdvisorsFourth quarter 2024 revenue of $22.5 million, a 11% increase as compared to the fourth quarter 2023U